Palabras clave
complicaciones cardiovasculares
COVID-19
tratamiento
SARS-CoV-2
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Analizar la relación entre el tratamiento farmacológico y las vacunas contra la COVID-19 y el agravamiento de las complicaciones cardiovasculares. Métodos: Se realizó una revisión integradora entre agosto y noviembre de 2023, utilizando las bases de datos de la Coordinación de Perfeccionamiento de Personal de Nivel Superior (CAPES), la Biblioteca Nacional de Medicina y los Institutos Nacionales de Salud (PUBMED), y la Biblioteca Virtual en Salud (BVS). Los descriptores empleados fueron“Heart Diseases”, “Cardiovascular complications”, “COVID-19”, “Treatment” y “SARS-CoV-2” con el operador booleano "AND". Se excluyeron revisiones y se incluyeron artículos en inglés publicados entre 2020 y 2023. Resultados: De los 19 artículos estudiados, 7 se centraron en el tratamiento farmacológico, lo que resultó en mejoras clínicas y aumento en el tiempo de supervivencia. Los 12 restantes, relacionados con las vacunas, mostraron que el riesgo de complicaciones cardiovasculares es raro, con mayor frecuencia en hombres jóvenes. Consideraciones finales: No se observaron incidencias significativas de complicaciones cardiovasculares en pacientes sometidos a tratamiento farmacológico o vacunación, destacando la importancia de ambos en la lucha contra la enfermedad.
Referencias
BIKDELI B, et al. Intermediate-Dose versus Standard-Dose Prophylactic: Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022; 122: 131-141.
CASARIN F, et al. AB1348 PERICARDITIS AFTER COVID-19 VACCINATION: a case series. Scientific Abstracts, 2023; 82: 1905.
CORRAO G, et al. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in lombardy, italy. Bmc Infectious Diseases, 2022; 22: 844.
DEFTEREOS S, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. Jama Network Open, 2020; 3(6): e2013136.
FADAH K, et al. Acute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult. Cureus, 2023; 12: e02929.
FANG E, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction And Targeted Therapy, 2023; 7: 94.1.
FARAHMAND R, et al. Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects. The American Journal of Cardiology, 2022; 164: 123-130.
FOLEGATTI P, et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2022; 40: 5248-5262.
HAJJO R, et al. Shedding Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines, 2021; 9: 1186.
INJAC R, et al. Global pandemic vaccine development, production and distribution challenges for the world population. International Journal Of Risk & Safety In Medicine, 2022; 33: 235-248.
KARLSTAD Ø, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. Jama Cardiology, 2022; 7: 600.
KLOK F, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 2020; 191: 145-147.
KYAW H, et al. COVID-19 mRNA Vaccine-Associated Myocarditis. Cureus, 2022; 14(1): e21009.
LOPES R, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. Jama, 2021; 325: 254.
MAARSE B, et al. Effect of hydroxychloroquine on the cardiac ventricular repolarization: a randomized clinical trial. British Journal of Clinical Pharmacology, 2021; 88: 1054-1062.
MARSHALL M, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics. 2021; 148(3): e2021052478
NÚÑEZ-GIL I, et al. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international hope covid-19 (health outcome predictive evaluation for covid-19) registry. American Heart Journal, 2021; 237: 104-115.
OSTROWSKI S, et al. Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. Frontiers In Immunology, 2021; 12.
PATONE M, et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation, 2022; 146: 743-754.
PRISMA. 2023. Disponível em: <http://www.prisma-statement.org/>. Acesso em: 8 nov. 2023.
SCHATZMAYR H. Novas perspectivas em vacinas virais. História, Ciências, Saúde-Manguinhos, 2003; 10: 655-669.
TAVARES C, et al. Alterações da ECA2 e Fatores de Risco para Gravidade da COVID-19 em Pacientes com Idade Avançada. Arquivos Brasileiros de Cardiologia, 2020; 115: 701-707.
WANG T, et al. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Annals Of Internal Medicine, 2023; 176: 515-523.
WITBERG G, et al. Myocarditis after COVID-19 Vaccination in a Large Health Care Organization. New England Journal of Medicine, 2021; 385: 2132-2139
YE X, et al. BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐CoV‐2 Infection Among Patients With Cardiovascular Disease. Journal of the American Heart Association, 2023; 12.